| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ... The Lancet 389 (10088), 2492-2502, 2017 | 4331 | 2017 |
| Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... JAMA oncology 6 (11), e204564-e204564, 2020 | 1110 | 2020 |
| Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis C Xu, YP Chen, XJ Du, JQ Liu, CL Huang, L Chen, GQ Zhou, WF Li, ... Bmj 363, 2018 | 526 | 2018 |
| Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study C Hsu, SH Lee, S Ejadi, C Even, RB Cohen, C Le Tourneau, JM Mehnert, ... Journal of Clinical Oncology 35 (36), 4050-4056, 2017 | 453 | 2017 |
| Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma AL Cheng, C Hsu, SL Chan, SP Choo, M Kudo Journal of hepatology 72 (2), 307-319, 2020 | 451 | 2020 |
| A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: a randomized trial C Hsu, CA Hsiung, IJ Su, WS Hwang, MC Wang, SF Lin, TH Lin, ... Hepatology 47 (3), 844-853, 2008 | 408 | 2008 |
| Chemotherapy‐induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study C Hsu, HH Tsou, SJ Lin, MC Wang, M Yao, WL Hwang, WY Kao, CF Chiu, ... Hepatology 59 (6), 2092-2100, 2014 | 302 | 2014 |
| Nivolumab (NIVO)+ ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... Journal of Clinical Oncology 37 (15_suppl), 4012-4012, 2019 | 258 | 2019 |
| Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis T Yau, C Hsu, TY Kim, SP Choo, YK Kang, MM Hou, K Numata, W Yeo, ... Journal of hepatology 71 (3), 543-552, 2019 | 238 | 2019 |
| Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma YY Shao, ZZ Lin, C Hsu, YC Shen, CH Hsu, AL Cheng Cancer 116 (19), 4590-4596, 2010 | 203 | 2010 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative … LT Chen, E Martinelli, AL Cheng, G Pentheroudakis, S Qin, ... Annals of Oncology 31 (3), 334-351, 2020 | 196 | 2020 |
| Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis Y Zou, WB Tsai, CJ Cheng, C Hsu, YM Chung, PC Li, SH Lin, MCT Hu Breast cancer research 10, 1-13, 2008 | 181 | 2008 |
| Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis YC Shen, CJ Chang, C Hsu, CC Cheng, CF Chiu, AL Cheng Cancer Epidemiology Biomarkers & Prevention 14 (8), 1986-1990, 2005 | 170 | 2005 |
| Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach YC Shen, C Hsu, LT Chen, CC Cheng, FC Hu, AL Cheng Journal of hepatology 52 (6), 889-894, 2010 | 165 | 2010 |
| Tumor heterogeneity in hepatocellular carcinoma: facing the challenges LC Lu, CH Hsu, C Hsu, AL Cheng Liver cancer 5 (2), 128-138, 2016 | 160 | 2016 |
| Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial CC Lin, C Hsu, CH Hsu, WL Hsu, AL Cheng, CH Yang Investigational new drugs 25, 77-84, 2007 | 153 | 2007 |
| Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur … CY Hsu, YC Shen, CW Yu, C Hsu, FC Hu, CH Hsu, BB Chen, SY Wei, ... Journal of hepatology 55 (4), 858-865, 2011 | 151 | 2011 |
| A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer JS Chen, C Hsu, NJ Chiang, CS Tsai, HH Tsou Annals of Oncology 26, 943-9, 2015 | 148 | 2015 |
| Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group SJ Kim, C Hsu, YQ Song, K Tay, XN Hong, J Cao, JS Kim, HS Eom, ... European journal of cancer 49 (16), 3486-3496, 2013 | 148 | 2013 |
| Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma CH Hsu, YC Shen, ZZ Lin, PJ Chen, YY Shao, YH Ding, C Hsu, AL Cheng Journal of hepatology 53 (1), 126-131, 2010 | 147 | 2010 |
